These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 17552518)

  • 21. Regulation of Glycogen Content in Astrocytes via Cav-1/PTEN/AKT/GSK-3β Pathway by Three Anti-bipolar Drugs.
    Jia S; Li B; Huang J; Verkhratsky A; Peng L
    Neurochem Res; 2018 Aug; 43(8):1692-1701. PubMed ID: 29968232
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evidence for antimanic efficacy of glycogen synthase kinase-3 (GSK3) inhibitors in a strain-specific model of acute mania.
    Kalinichev M; Dawson LA
    Int J Neuropsychopharmacol; 2011 Sep; 14(8):1051-67. PubMed ID: 21208504
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of valproic acid derivatives on inositol trisphosphate depletion, teratogenicity, glycogen synthase kinase-3beta inhibition, and viral replication: a screening approach for new bipolar disorder drugs derived from the valproic acid core structure.
    Eickholt BJ; Towers GJ; Ryves WJ; Eikel D; Adley K; Ylinen LM; Chadborn NH; Harwood AJ; Nau H; Williams RS
    Mol Pharmacol; 2005 May; 67(5):1426-33. PubMed ID: 15687223
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition.
    Leng Y; Liang MH; Ren M; Marinova Z; Leeds P; Chuang DM
    J Neurosci; 2008 Mar; 28(10):2576-88. PubMed ID: 18322101
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lithium and neuropsychiatric therapeutics: neuroplasticity via glycogen synthase kinase-3beta, beta-catenin, and neurotrophin cascades.
    Wada A
    J Pharmacol Sci; 2009 May; 110(1):14-28. PubMed ID: 19423950
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of GSK-3 in treatment-resistant depression and links with the pharmacological effects of lithium and ketamine: A review of the literature.
    Costemale-Lacoste JF; Guilloux JP; Gaillard R
    Encephale; 2016 Apr; 42(2):156-64. PubMed ID: 26995153
    [TBL] [Abstract][Full Text] [Related]  

  • 27. AKT kinase activity is required for lithium to modulate mood-related behaviors in mice.
    Pan JQ; Lewis MC; Ketterman JK; Clore EL; Riley M; Richards KR; Berry-Scott E; Liu X; Wagner FF; Holson EB; Neve RL; Biechele TL; Moon RT; Scolnick EM; Petryshen TL; Haggarty SJ
    Neuropsychopharmacology; 2011 Jun; 36(7):1397-411. PubMed ID: 21389981
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lithium- and valproate-induced alterations in circadian locomotor behavior in Drosophila.
    Dokucu ME; Yu L; Taghert PH
    Neuropsychopharmacology; 2005 Dec; 30(12):2216-24. PubMed ID: 15956996
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A molecular cell biology of lithium.
    Williams R; Ryves WJ; Dalton EC; Eickholt B; Shaltiel G; Agam G; Harwood AJ
    Biochem Soc Trans; 2004 Nov; 32(Pt 5):799-802. PubMed ID: 15494019
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glycogen synthase kinase-3β in patients with bipolar I disorder: results from a prospective study.
    Jacoby AS; Munkholm K; Vinberg M; Joaquim HG; Talib LL; Gattaz WF; Kessing LV
    Bipolar Disord; 2016 Jun; 18(4):334-41. PubMed ID: 27325150
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association study of the glycogen synthase kinase-3beta gene polymorphism with prophylactic lithium response in bipolar patients.
    Szczepankiewicz A; Rybakowski JK; Suwalska A; Skibinska M; Leszczynska-Rodziewicz A; Dmitrzak-Weglarz M; Czerski PM; Hauser J
    World J Biol Psychiatry; 2006; 7(3):158-61. PubMed ID: 16861141
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glycogen synthase kinase-3: a target for novel bipolar disorder treatments.
    Gould TD; Zarate CA; Manji HK
    J Clin Psychiatry; 2004 Jan; 65(1):10-21. PubMed ID: 14744163
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Haplotype analysis of GSK-3β gene polymorphisms in bipolar disorder lithium responders and nonresponders.
    Iwahashi K; Nishizawa D; Narita S; Numajiri M; Murayama O; Yoshihara E; Onozawa Y; Nagahori K; Fukamauchi F; Ikeda K; Ishigooka J
    Clin Neuropharmacol; 2014; 37(4):108-10. PubMed ID: 24992082
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Highly potent and specific GSK-3beta inhibitors that block tau phosphorylation and decrease alpha-synuclein protein expression in a cellular model of Parkinson's disease.
    Kozikowski AP; Gaisina IN; Petukhov PA; Sridhar J; King LT; Blond SY; Duka T; Rusnak M; Sidhu A
    ChemMedChem; 2006 Feb; 1(2):256-66. PubMed ID: 16892358
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs.
    Gould TD; Manji HK
    Neuropsychopharmacology; 2005 Jul; 30(7):1223-37. PubMed ID: 15827567
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structure-activity relationship (SAR) studies of synthetic glycogen synthase kinase-3β inhibitors: A critical review.
    Xu M; Wang SL; Zhu L; Wu PY; Dai WB; Rakesh KP
    Eur J Med Chem; 2019 Feb; 164():448-470. PubMed ID: 30616053
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons.
    Yasuda S; Liang MH; Marinova Z; Yahyavi A; Chuang DM
    Mol Psychiatry; 2009 Jan; 14(1):51-9. PubMed ID: 17925795
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glycogen synthase kinase 3beta as a likely target for the action of lithium on circadian clocks.
    Padiath QS; Paranjpe D; Jain S; Sharma VK
    Chronobiol Int; 2004 Jan; 21(1):43-55. PubMed ID: 15129823
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium.
    O'Brien WT; Harper AD; Jové F; Woodgett JR; Maretto S; Piccolo S; Klein PS
    J Neurosci; 2004 Jul; 24(30):6791-8. PubMed ID: 15282284
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytoprotection by lithium and valproate varies between cell types and cellular stresses.
    Lai JS; Zhao C; Warsh JJ; Li PP
    Eur J Pharmacol; 2006 Jun; 539(1-2):18-26. PubMed ID: 16678157
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.